16,978 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft bought a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,978 shares of the company’s stock, valued at approximately $204,000. Baader Bank Aktiengesellschaft owned 0.05% of Delcath Systems as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in Delcath Systems during the third quarter valued at $102,000. Barclays PLC purchased a new position in Delcath Systems during the 3rd quarter valued at about $104,000. Jane Street Group LLC acquired a new position in shares of Delcath Systems in the 3rd quarter valued at about $110,000. Riverwater Partners LLC purchased a new stake in shares of Delcath Systems in the third quarter worth approximately $161,000. Finally, Virtu Financial LLC acquired a new stake in shares of Delcath Systems during the third quarter worth approximately $289,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Price Performance

Delcath Systems stock opened at $15.60 on Friday. Delcath Systems, Inc. has a one year low of $3.70 and a one year high of $16.44. The company’s fifty day moving average price is $12.54 and its two-hundred day moving average price is $10.39. The company has a market capitalization of $498.73 million, a price-to-earnings ratio of -11.56 and a beta of 0.87.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Craig Hallum increased their price objective on Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Canaccord Genuity Group restated a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.